Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2014-09-03
Target enrollment:
Participant gender:
Summary
This research study is evaluating an investigational combination of four drugs called
Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a
possible treatment for newly diagnosed multiple myeloma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center